Roche is set to raise treatment levels for cancer with its Premier Integrated Labs collaboration in its bid to increase awareness and understanding of Comprehensive Genomic Profiling (CGP) and improve patient access to CGP patients in Malaysia.
Comprehensive Genomic Profiling tailors personalised cancer treatment for patients. With a single test, CGP can analyse a broad panel of genes that are known to drive cancer growth. This type of testing produces comprehensive patient reports with broad and deep assessments of the possible underlying cancer drivers.
Heng Chai Yin, General Manager of Roche Diagnostics (M) Sdn. Bhd. shared, “At Roche, we have a passion for innovation and we strive to improve patient access in Malaysia as healthcare that is built on people’s needs, strong data and clinical insights is healthcare that saves lives.” She added that Roche understands the importance of the role cancer genomics can play and is actively working towards increasing the awareness and understanding of CGP, staying true to Roche’s vision of continuously innovating diagnostics, shaping healthcare, and changing lives.
